

Journal of dental research (2002) 81(12):845-850.

Cathelicidin antimicrobial peptides are expressed in salivary glands and saliva

Murakami, M.; Ohtake, T.; Dorshner, RA.; Gallo, RL.

### **RESEARCH REPORTS**

Clinical

# M. Murakami, T. Ohtake, R.A. Dorschner, and R.L. Gallo\*

Division of Dermatology, University of California San Diego; and VA San Diego Healthcare Center, San Diego, CA 92161, USA; \*corresponding author, rgallo@vapop.ucsd.edu

J Dent Res 81(12):845-850, 2002

### ABSTRACT

The expression of antimicrobial peptides at epithelial surfaces such as skin, lung, and intestine is thought to provide protection against infection. Cathelicidin antimicrobial peptides are essential for the protection of skin against invasive bacterial infection. To determine if cathelicidins are also present in the oral cavity, we examined the expression of both mRNA and protein in mice and human saliva. The murine cathelicidin (CRAMP) was detected in the adult by reverse-transcription/polymerase chain-reaction (RT-PCR), and in embryonic, newborn, and adult tissues by in situ hybridization and immunohistochemistry. CRAMP mRNA and protein were localized to the salivary glands, specifically in acinar cells of the submandibular gland and palatine minor glands, as well as in lingual epithelium and palatal mucosa. In man, the human cathelicidin LL-37 was detected in human saliva by Western blotting. These results indicate that cathelicidins are present in the salivary system, in some oral epithelia, and in saliva, contributing to broad-spectrum defense of the oral cavity.

**KEY WORDS:** oral mucosa, CRAMP, LL-37, innate immunity.

# Cathelicidin Antimicrobial Peptides are Expressed in Salivary Glands and Saliva

### INTRODUCTION

**M**any peptides have been discovered based on their ability to kill or inhibit the proliferation of pathogenic micro-organisms (Zasloff, 2002). Antimicrobial peptides are widely known in plants, insects, and animals, where they provide a first line of defense against invading pathogens. In humans, antimicrobial peptides of three families have received considerable attention: the cathelicidins (Frohm *et al.*, 1997; Zaiou and Gallo, 2002), the defensins ( $\alpha$ - and  $\beta$ -) (Zhao *et al.*, 1996), and the histatins (Oppenheim *et al.*, 1988). When studied in vitro, these peptides have distinct and overlapping antimicrobial activity (Bals, 2000; Yang *et al.*, 2001).

Cathelicidins are a widely expressed family of mammalian antimicrobial peptides that contain a highly conserved signal sequence and cathelin domain but show substantial heterogeneity in the C-terminal domain encoding the mature active peptide (Zanetti *et al.*, 1995). Cathelicidins are found in many mammals, including primates, ungulates, rodents, and rabbits (Zaiou and Gallo, 2002). The murine cathelicidin CRAMP (Cathelin-related Antimicrobial Peptide) (Gallo *et al.*, 1997) closely resembles human LL-37, first isolated from human granulocytes (Gudmundsson *et al.*, 1996). Both CRAMP and LL-37 antimicrobial domains show considerable structural homology, are synthesized as preproproteins (Zanetti *et al.*, 1995), and are processed from an inactive precursor form to an active mature peptide to kill bacteria. In skin, these antimicrobial peptides show identical patterns of expression and are greatly increased after wounding occurs (Dorschner *et al.*, 2001).

Cathelicidins have broad-spectrum activity against Gram-positive and Gram-negative bacteria as well as fungi and envelope viruses (Bals et al., 1998; Johansson et al., 1998; Turner et al., 1998; Dorschner et al., 2001). Histatin peptides are microbicidal, possibly involved in maintaining the acquired enamel pellicle, and enhance the glycolytic activity of certain oral micro-organisms. Histatin and calprotectin have antimicrobial activity against Candida (Oppenheim et al., 1988; Eversole et al., 1993). β-defensins have antimicrobial activity against Gram-negative bacteria such as E. coli, some Gram-positive bacteria, and Candida albicans (Dale and Krisanaprakornkit, 2001; Lehrer and Ganz, 2002). Bdefensins have also been specifically investigated with respect to their activity against oral bacteria; Capnocytophaga spp. are sensitive to oxygen-independent killing by human defensins, whereas the A. actinomycetemcomitans and E. corrodens strains were resistant (Miyasaki et al., 1990). Therefore, the co-expression of cathelicidins and  $\beta$ -defensing in saliva with peptides such as histatin and calprotectin provides a powerful combined natural antibiotic barrier.

In the oral cavity, antimicrobial peptides of the  $\beta$ -defensin and histatin families have been described (vanderSpek *et al.*, 1990; Weinberg *et al.*, 1998).  $\beta$ -defensins and histatins have antimicrobial activity distinct from that of cathelicidins, but are also active against certain Gram-positive and Gram-negative bacteria, fungi, and viruses (Weinberg *et al.*, 1998; Huttner and Bevins, 1999). In contrast to the expression of human betadefensins hBD-1 and hBD-2 described in gingiva, LL-37 has been found in lesser amounts and mostly within neutrophils (Dale *et al.*, 2001). Since cathelicidins and  $\beta$ defensins act synergistically to kill several strains of bacteria (Nagaoka *et al.*, 2000), we evaluated the oral cavity for constitutive expression of cathelicidins in salivary glands as a potential additional mode of delivery of antimicrobial peptides under non-inflammatory conditions.

### **MATERIALS & METHODS**

#### **Tissue Sampling**

BALB/C mice, including 17-day-gestation embryos (E-17), Day-4 newborns, and adults (Jackson Laboratory, Bar Harbor, ME), were housed in a pathogen-free barrier facility. Animal use was approved by the San Diego VA Subcommittee on animal studies, protocol 99-035. Following the animals' death by CO<sub>2</sub>, tissue was immediately embedded in optimal cutting temperature (OCT) compound. The submandibular gland of the adult mouse or various tissues (tongue, palate mucosa, buccal mucosa, and gingiva) was microdissected for extraction of total RNA. All specimens were stored at -80°C until use. For immunohistochemistry, sections were cut at 10 µm. For in situ hybridization, fresh-frozen sections were cut at 10 µm, fixed with 4% paraformaldehyde (PFA) for 10 min at room temperature, and immersed in 0.1% active diethyl pyrocarbonate (DEPC) in phosphate-buffered saline (PBS:137 mM NaCl, 2.7 mM KCL, 4.3 mM Na<sub>2</sub>HPO<sub>4</sub>-H<sub>2</sub>O, 1.4 mM KH<sub>2</sub>PO<sub>4</sub>) at 4°C overnight before being processed.

#### Human Saliva

For Western-blot analysis, human saliva was collected from two healthy volunteers. Crude saliva (500  $\mu$ L) was twice centrifuged at 15,000 r.p.m. for 10 min, then supernatant-acidified by the addition of 500  $\mu$ L of 1 M HCl/1%TFA, concentrated by lyophilization, and re-suspended in 50  $\mu$ L of doubly-glass-distilled water (DDW). All samples were stored at -20°C until use. Total protein concentration of the collected saliva was evaluated by BCA assay (protein assay reagent, Pierce, Rockford, IL, USA).

#### Reverse-transcription/Polymerase Chain-reaction (RT-PCR)

Total RNA was extracted from freshly dissected tissues by means of an RNeasy Mini kit (Qiagen, Valencia, CA, USA). cDNA was prepared from 1 µg of total RNA by means of a RETROscript kit (Ambion, Woodward, Austin, TX, USA). PCR protocol for amplification of CRAMP cDNA was as previously described, with 35 cycles (Dorschner et al., 2001). PCR amplification of CRAMP was performed with the forward primer (5'-AGGAGATCTT-GGGAACCATGCAGTT-3') and the reverse primer (5'-GCAGATCTACTGTCCGGCTGAGGTA-3') for a 532-bp product. Each of these primers has a Bgl-II restriction enzyme before both 5' ends. Amplification of 18S rRNA was performed in parallel for all samples with a QuantumRNA classic 18S internal standard kit (Ambion, Woodward, Austin, TX, USA). For a positive control template, mouse bone marrow total RNA was used, and the PCR product was directly sequenced and found to be identical to CRAMP.

#### In situ Hybridization

For *in situ* probes, a PCR product of CRAMP mature form (CRmf, 159 bp) was amplified and sequenced for confirmation of identity, then inserted into the PCR II-TOPO vector (TOPO TA Cloning version M, Invitrogen, Carlsbad, CA, USA). Plasmid DNA was purified by means of a DNA Extraction Maxi Kit (Qiagen, Valencia, CA, USA) and linearized with restriction enzymes (*BglII* and *XbaI*) for anti-sense and sense RNA probe. Digoxigenin-labeled riboprobes were prepared on linearized plasmid by means of the digoxigenin (DIG) RNA labeling kit (SP6/T7, Roche Molecular Biochemicals, Mannheim, Germany). To confirm the specificity of the labeled probes, we blotted 2  $\mu$ L of the plasmid cDNA for CRmf on nitrocellulose filters (OSMONICS, Westborough, MA, USA).

Fresh-frozen sections were fixed with 4% PFA for 10 min at room temperature, and pre-treated with 1 µg/mL proteinase K in PBS for 15 min at 37°C. Sections were treated with a 1 M triethanolamine solution (pH 8.0) containing 0.25% acetic anhydride for 15 min at 37°C, washed with PBS at least 3 times, then treated with 100% ethanol for 5 min, and dried. Pre-hybridization was performed with 50% formamide in 2x sodium saline citrate (SSC: 3 M sodium chloride, 0.03 M sodium citrate) for 30 min at 45°C. Sections were then hybridized for 16 hrs at 45°C with sense or antisense DIGlabeled cRNA probes (1 µg/mL) in hybridization solution (1 mg/mL yeast tRNA, 20 mM Tris-HCl buffer [pH 8.0], 2.5 mM EDTA, 1x Denhardt's solution, 0.3 M NaCl, 50% de-ionized formamide, 50% dextran sulfate). Stringent washing was done for 60 min at 45°C with 50% formamide in 2x SSC, and for 10 min at 37°C with 2x SSC; samples were then treated with RNase-A (Roche Molecular Biochemicals, Mannheim, Germany) for 30 min at 37°C. After being washed with the 2x SSC for 30 min at 37°C, sections were reacted with anti-DIG alkaline phosphate Fab fragment antibody (1:500, in PBS, Roche Molecular Biochemicals, Mannheim, Germany) for 5 hrs at RT. Alkaline phosphate was visualized by incubation with 5bromo-4-chloro-3-indolyl phosphate (X-phosphate) and nitroblue tetrazolium (NBT) with addition of levamisole solution (DAKO, Carpinteria, CA, USA) overnight at room temperature (RT). Methyl green stain was used for nuclear counterstain. RNA preservation in tissues was confirmed by similar hybridizations by means of a keratin 14 antisense probe (insert 175 bp).

#### Immunohistochemistry


For CRAMP protein, rabbit anti-CRAMP polyclonal antibody was used as previously described (Dorschner et al., 2001; Pestonjamasp et al., 2001). Tissue sections were immersed in PBS after 4% PFA fixation for 20 min, and endogenous peroxidase activity blocked with a 30-minute incubation in 0.3% H<sub>2</sub>O<sub>2</sub> in methanol. Sections were blocked with 2% goat serum in PBS for 30 min, and incubated with primary antibody, rabbit anti-CRAMP polyclonal antibody (0.8 µg/mL) in PBS, 3% bovine serum albumin for 60 min. Signal was detected with a Vectorstain ABC Elite Rabbit kit (Vector Laboratories, Burlingame, CA, USA) and processed by means of an ABC kit (Vector Laboratories, Burlingame, CA, USA). As a negative control, the polyclonal antibody was replaced by normal rabbit pre-immune IgG diluted with PBS containing 3% BSA at the same protein concentration as the primary antibody. Finally, sections were incubated in 0.02% diaminobenzidine with 0.05% H<sub>2</sub>O<sub>2</sub> in PBS for 5 min and counterstained with Mayer's hematoxylin for 30 sec. The specificity of the primary antibody reaction has been confirmed in separate experiments by absorption of the anti-CRAMP with excess amounts of synthetic peptide.

CRAMP

185

CRAMP

185



the blocking solution) was incubated with the membrane for 60 min at RT. After the membrane was washed with 0.1% TTBS, it was immersed in ECL solution (Western Lightning Chemiluminescence Reagents Plus, New Lifescience Products, Boston, MA, USA) for 60 sec, then exposed to x-ray film (Kodak). Synthetic LL-37 peptide derived by Synpep Corporation (Dublin, OR, USA) was used for positive control of Western blot.

For confirmation of the identity of the band detected by Western blot, the filter was stripped of antibody (62.5 mM Tris-HCl [pH 6.8], 2% SDS, 100 mM  $\beta$ -mercaptoethanol) at 50°C for 30 min, then reacted with a newly derived chicken anti-cathelin antibody (1:10000) and horseradish-peroxidase-labeled goat antichicken IgY (1:10000; Aves Labs.). The filter was again stripped of antibody, then reacted with a newly derived chicken anti-LL37 antibody (1:2000) and horseradish-peroxidase-labeled goat antichicken IgY according to the same method described above.

#### RESULTS

# CRAMP mRNA is Expressed in the Salivary Gland and Oral Mucosa

To determine if CRAMP mRNA could be detected in the oral cavity of the adult mouse, we first performed RT-PCR on microdissected tissues. CRAMP mRNA was detected in the salivary gland (submandibular gland), tongue, gingival, and palatal mucosal tissues, respectively (Fig. 1). No CRAMP was detected in buccal mucosa.

For further exploration and specific confirmation of the expression of cathelicidin in the oral cavity, *in situ* hybridization was performed. Non-radioactive *in situ* hybridization with digoxigenin-labeled cRNA anti-sense probes for CRmf




Figure 2. CRAMP mRNA is expressed in the submandibular (salivary) gland and oral mucosa. CRAMP mRNA is localized by *in situ* hybridization with specific anti-sense CRAMP cRNA probes. Tissues were obtained from normal adult mice (A,D), newborn Day-4 mice (B,E,G-L), and fetal mice at day 17 of gestation (E17) (C,F). All submandibular glands (adult, D-4, E-17) show CRAMP mRNA expression (A-C), as do the palatine minor salivary glands (G). In the salivary glands, CRAMP mRNA expression is seen in the acinar cells, but not in ductal cells. In gingiva and palatal mucosa, CRAMP mRNA is located in the basal cell layer and a few suprabasal cell layers (H, and upper layer in I), and the epithelium of the dorsum of the tongue shows mRNA in whole epidermis (I, lower layer). Sense cRNA probes show no signal in any tissue (D-F, J-L). Original magnification: x400.

**Figure 1.** CRAMP mRNA is detectable in salivary glands by RT-PCR. A  $1-\mu$ g quantity of total RNA was used for each RT reaction. Bone marrow used as a positive control shows an intense band at the expected size. Salivary glands (submandibular) obtained from 3 separate dissections (#1, #2, #3) and tongue samples from 2 separate dissections, gingiva and palatal mucosa, show faint bands for CRAMP. CRAMP was not detected in buccal mucosa from 2 dissections or where water (DW) was used as a negative control. 18S RNA was amplified from duplicate samples. The ladder is 10  $\mu$ L of the phi-X 174/HaeIII size marker.

#### Western-blot Analysis

Rabbit anti LL-37 polyclonal antibody for immunostaing was kindly provided by Dr. Birgitta Agerberth (Microbiology and Tumorbiology Center, Stockholm, Sweden). This antibody was derived against the entire LL-37 peptide (Agerberth *et al.*, 1995; Frohm *et al.*, 1997).

Chicken polyclonal antibodies were derived against LL-37 mature form and cathelin domain (CATH) peptides by Aves Labs. (Tigard, OR, USA). Peptide amino acid sequences used for

immunization were CZQRIKD-FLRNLVPRTES and CZNLYR-LLDLDPRPTMD for LL-37 and CATH, thus identifying domains in the C-terminal antimicrobial peptide and the precursor protein, respectively. IgY fractions were affinity-purified with the respective immunizing peptides. The stock concentrations of the antibodies were 1.25 mg/mL and 1.62 mg/mL for LL-37 and cathelin.

Samples were separated by 4-20% gradient SDS/polyacrylamide gel electrophoresis (Express gels, ISC BioExpress, Kaysville, VT, USA), and transferred to nitrocellulose membrane (OSMONICS, Westborough, MA, USA). Membrane was blocked (0.1% TTBS: 5% non-fat milk in 0.1% Tween 20/Tris buffered saline ([BS: 150 mM NaCl, 10 mM Tris Base, pH 7.4]) for 60 min at RT, and then rabbit anti-LL37 polyclonal antibody (1:3000 in the blocking solution) was incubated with the membrane for 60 min at RT. After




Figure 3. CRAMP protein is expressed in the submandibular (salivary) gland, and oral mucosa. CRAMP protein in submandibular glands of adult mouse (A), E-17 embryonic mouse (B), newborn Day-4 mouse (C), and palatine minor salivary gland of the newborn (G). Newborn gingiva (H) and tongue (I, lower layer) also show CRAMP expression. In newborn palatal mucosa, CRAMP is located in the basal cell layer and a few suprabasal cells (I, upper layer). For negative controls, pre-immune rabbit IgG (D-F, J-L) was used. Original magnifications: x400.




Figure 4. Human saliva contains the cathelicidin LL-37. SDS-PAGE of human saliva extract and synthetic LL-37 peptide was evaluated by Western blot with rabbit antibody against full-length LL-37. Membrane was then stripped and re-probed with chicken antibody against the cathelin immature domain (CATH). Membrane was again stripped and re-probed with a unique chicken anti-LL-37 peptide antibody. Arrow at A corresponds to expected size of full-length human cathelicidin. Arrow at B (14 kDa) is intermediate size suggesting partial processing of cathelicidin. Arrow at C corresponds to 5-kDa mature LL-37 antimicrobial peptide.

showed that the CRAMP mRNA was expressed in tissues previously found positive by RT-PCR. The signal was detected in the submandibular gland at all developmental stages (E17 to adult) (Figs. 2A-2C), and in newborn palatine minor salivary glands (Fig. 2G), gingiva (Fig. 2H), palatal mucosal tissue, and dorsum of the tongue (Fig. 2I). In the salivary glands, intense signal was found in the cytoplasm of the acinar cells, but no mRNA was found in the intercalated and striated ducts (Figs. 2A-2C, 2G). In the squamous mucosal tissue of the gingival and palatal mucosa, the signal was located in the basal cell layer and some suprabasal layer (Figs. 2H, 2I). In the dorsum of tongue, the mRNA was detected in whole epidermis, and spotty strong signals were located in the upper layer more than in the basal cell layer (Fig. 2I). No signal was detected with sense probe as control in every tissue (Figs. 2D-2F, 2J-2L).

## CRAMP Protein is Expressed in the Salivary Glands and Oral Mucosal Tissues

For further exploration and confirmation of cathelicidin expression at the protein level, oral tissue was examined for CRAMP by immunohistochemistry. Specific anti-CRAMP antibody showed abundant localization in the submandibular glands of the adult (Fig. 3A), D-4 newborn (Fig. 3C), and the E-17 embryo (Fig. 3B). D-4 mouse palatine minor salivary gland also showed expression (Fig. 3G). CRAMP was mainly located in the cytoplasm, especially around the nucleus in serous-type acini and mucinous-type acini. Some ductal cells of the intercalated and striated duct epithelium also showed protein expression. CRAMP was also expressed in the whole epidermis of gingiva (Fig. 3H), palatal mucosa, and the dorsum of the tongue (Fig. 3I) in newborns.

#### Human Cathelicidin LL-37 is Expressed in Saliva

The detection of cathelicidin protein and mRNA in the murine oral cavity suggested that this antimicrobial peptide may also be present in human saliva. To study this, we evaluated normal human saliva by Western blot with three antibodies independently derived against distinct domains of the full-length cathelicidin gene product (anti-CATH and anti-LL-37).

LL-37 protein expression was detectable in crude extracts of human saliva (Fig. 4). Three bands were detected with rabbit anti-LL37, two with chicken anti-cathelin domain, and two with chicken anti-LL37 used for further confirmation of the identity of the proteins seen by Western blot. Bands at 18 kDa correspond to the full-length cathelicidin, and additional 14-kDa bands were detectable with all three antibodies. Bands at 5 kDa correspond with the mature LL-37 peptide. Chicken anti-LL-37 had lower sensitivity than rabbit anti-LL-37, as seen by comparison of reactivity to the LL-37 synthetic peptide.

#### DISCUSSION

Oral epithelium is constantly exposed to a variety of microbial pathogens. Antimicrobial peptides are essential elements of epithelial defense participating in a variety of immune mechanisms, both direct and indirect (Zasloff, 2002). The expression of defensins, in particular hBD-1 and hBD-2, has previously been described in major salivary glands, tongue, gingiva, and buccal mucosa (Dale and Krisanaprakornkit, 2001). Cathelicidins are expressed in various epithelia under both constitutive and inflamed conditions such as woundhealing (Frohm et al., 1997; Dorschner et al., 2001). This family of antimicrobial peptides can inhibit the growth of oral pathogens in vitro (Guthmiller et al., 2001) but has previously been described as a relatively minor part of the antimicrobial milieu of the mouth (Dale and Krisanaprakornkit, 2001). In this investigation, we sought to use the mouse model to explore whether cathelicidins are expressed in significant amounts in the oral cavity, thus providing an additional innate antimicrobial defense system. Our results show that the murine cathelicidin CRAMP is expressed primarily in the salivary

glands. Furthermore, analysis of human saliva shows that cathelicidin is also present in the human mouth, as demonstrated by the presence of LL-37 in both its mature and immature forms.

To explore the expression of cathelicidin, we microdissected individual tissues from the mouth and performed semi-quantitative PCR. These results suggested that cathelicidin mRNA was present in the oral cavities of mice from the late embryonic period to adult. The high sensitivity and potential for false-positive results with PCR necessitated further analysis by in situ hybridization and immunohistochemistry. Both techniques confirmed expression of cathelicidin in secretory epithelia and mucosal structures. CRAMP mRNA was detected only in acinar cells, and CRAMP protein in both acinar and ductal cells. In contrast, hBD-1 had been previously shown in the minor salivary gland and ductal cells, with no expression found in acinar cells (Sahasrabudhe et al., 2000). These results show that secretion of cathelicidin and defensin differs in the salivary glands, with a possibility of distinct regulation as well as mutual cooperation against oral pathogens.

To confirm that these observations in mouse salivary glands are relevant to human oral defense, we investigated human saliva. Using a combination of distinct antibodies against different domains of human cathelicidin LL-37, we showed that this peptide is abundantly present and apparently processed into several forms. Using antibodies derived against the mature peptide and the 18-kDa immature form, we could see a 14-kDa band and the mature 37-amino-acid peptide. However, analysis of human saliva with a chicken anti-LL-37 antibody derived against a carboxy-terminal peptide fragment from LL-37 could not detect the 18-kDa immature form. This likely reflects epitope masking in the mature form, since both antibodies could detect the mature form of LL-37, and a third antibody directed against the cathelin domain detected both the 18- and 14-kDa forms. The function of these various processed forms of cathelicidin remains unknown.

In the oral cavity, multiple peptides and proteins with antimicrobial action have been described. For example, lysozyme (Tobgi *et al.*, 1988), calprotectin (Eversole *et al.*, 1993),  $\beta$ -defensins (Mathews *et al.*, 1999; Dale and Krisanaprakornkit, 2001; Dunsche *et al.*, 2001), and histatin (Oppenheim *et al.*, 1988; vanderSpek *et al.*, 1990) have been identified. Cathelicidin expression has been previously described in tongue and buccal mucosa (Frohm Nilsson *et al.*, 1999). However, although cathelicidin expression in salivary glands. The significance of the current observations of cathelicidin expression is therefore the recognition of a natural antibiotic previously shown to be essential to skin defense as an additional antimicrobial peptide participating in oral protection.

Like all reports of *in vitro* antimicrobial activity, the interpretation of antimicrobial results depends on the assay system used. For example, oral bacteria such as *A. actinomycetemcomitans, C. sputigena, C. gingivalis,* and *C. ochracea* have been shown to be sensitive to LL-37 in 10 mM sodium phosphate with 1% TSB solution, but not in high salt (Tanaka *et al.,* 2000). LL-37 has been reported as ineffective in tryptic soy broth (TSB)-based medium for oral bacteria such as *A. actinomycetemcomitans, F. nucleatum, P. gingivalis, S.* 

sanguis, C. albicans, C. kurusei, and C. tropicalis, with no correlation with salt concentration (Guthmiller *et al.*, 2001). Such conflicting results suggest that caution be applied to extrapolation of data from the *in vitro* system to conclusions regarding *in vivo* immune defense of the mouth. Nevertheless, the synergistic action of the previously described oral antimicrobial peptides supports their role in host defense (Nagaoka *et al.*, 2000; Dale and Krisanaprakornkit, 2001).

Further study of the combined activities and regulation of oral antimicrobial peptides will greatly advance our understanding of this system of epithelial defense. Direct analysis of the individual contribution of each peptide to antimicrobial action is needed. As information continues to accumulate, it has become clear, however, that unique systems of gene regulation and protein processing contribute to the functions of these molecules in different tissues. In mammals, cathelicidins are likely to play an important role in host defense at multiple epithelial surfaces and may provide important diagnostic and therapeutic advances toward disease resistance. These observations have led to an associated human periodontal disease. A deficiency in salivary *LL*-37 correlates with severe periodontal disease in *morbus Kostmann* (Putsep *et al.*, 2002)

#### ACKNOWLEDGMENTS

This work was supported by a VA Merit award and by NIH grant AI48176 (RG), and by the Japan-North America Medical Exchange Foundation (MM). We thank Prof. T. Koji (Department of Histology and Cell Biology, Nagasaki University School of Medicine, Japan) for technical advice.

#### REFERENCES

- Agerberth B, Gunne H, Odeberg J, Kogner P, Boman HG, Gudmundsson GH (1995). FALL-39, a putative human peptide antibiotic, is cysteine-free and expressed in bone marrow and testis. *Proc Natl Acad Sci USA* 92:195-199.
- Bals R (2000). Epithelial antimicrobial peptides in host defense against infection. *Respir Res* 1:141-150.
- Bals R, Wang X, Zasloff M, Wilson JM (1998). The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. *Proc Natl Acad Sci USA* 95:9541-9546.
- Dale BA, Krisanaprakornkit S (2001). Defensin antimicrobial peptides in the oral cavity. *J Oral Pathol Med* 30:321-327.
- Dale BA, Kimball JR, Krisanaprakornkit S, Roberts F, Robinovitch M, O'Neal R, et al. (2001). Localized antimicrobial peptide expression in human gingiva. J Periodontal Res 36:285-294.
- Dorschner RA, Pestonjamasp VK, Tamakuwala S, Ohtake T, Rudisill J, Nizet V, et al. (2001). Cutaneous injury induces the release of cathelicidin anti-microbial peptides active against group A Streptococcus. J Invest Dermatol 117:91-97.
- Dunsche A, Acil Y, Siebert R, Harder J, Schroder JM, Jepsen S (2001). Expression profile of human defensins and antimicrobial proteins in oral tissues. J Oral Pathol Med 30:154-158.
- Eversole LR, Miyasaki KT, Christensen RE (1993). Keratinocyte expression of calprotectin in oral inflammatory mucosal diseases. *J Oral Pathol Med* 22:303-307.
- Frohm M, Agerberth B, Ahangari G, Stahle-Backdahl M, Liden S, Wigzell H, *et al.* (1997). The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes

during inflammatory disorders. J Biol Chem 272:15258-15263.

- Frohm Nilsson M, Sandstedt B, Sorensen O, Weber G, Borregaard N, Stahle-Backdahl M (1999). The human cationic antimicrobial protein (hCAP18), a peptide antibiotic, is widely expressed in human squamous epithelia and colocalizes with interleukin-6. *Infect Immun* 67:2561-2566.
- Gallo RL, Kim KJ, Bernfield M, Kozak CA, Zanetti M, Merluzzi L, *et al.* (1997). Identification of CRAMP, a cathelin-related antimicrobial peptide expressed in the embryonic and adult mouse. *J Biol Chem* 272:13088-13093.
- Gudmundsson GH, Agerberth B, Odeberg J, Bergman T, Olsson B, Salcedo R (1996). The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. *Eur J Biochem* 238:325-332.
- Guthmiller JM, Vargas KG, Srikantha R, Schomberg LL, Weistroffer PL, McCray PB Jr, *et al.* (2001). Susceptibilities of oral bacteria and yeast to mammalian cathelicidins. *Antimicrob Agents Chemother* 45:3216-3219.
- Huttner KM, Bevins CL (1999). Antimicrobial peptides as mediators of epithelial host defense. *Pediatr Res* 45:785-794.
- Johansson J, Gudmundsson GH, Rottenberg ME, Berndt KD, Agerberth B (1998). Conformation-dependent antibacterial activity of the naturally occurring human peptide LL-37. J Biol Chem 273:3718-3724.
- Lehrer RI, Ganz T (2002a). Defensins of vertebrate animals. *Curr* Opin Immunol 14:96-102.
- Lehrer RI, Ganz T (2002b). Cathelicidins: a family of endogenous antimicrobial peptides. *Curr Opin Hematol* 9:18-22.
- Mathews M, Jia HP, Guthmiller JM, Losh G, Graham S, Johnson GK, *et al.* (1999). Production of beta-defensin antimicrobial peptides by the oral mucosa and salivary glands. *Infect Immun* 67:2740-2745.
- Miyasaki KT, Bodeau AL, Selsted ME, Ganz T, Lehrer RI (1990). Killing of oral, Gram-negative, facultative bacteria by the rabbit defensin, NP-1. Oral Microbiol Immunol 5:315-319.
- Nagaoka I, Hirota S, Yomogida S, Ohwada A, Hirata M (2000). Synergistic actions of antibacterial neutrophil defensins and cathelicidins. *Inflamm Res* 49:73-79.
- Nizet V, Ohtake T, Lauth X, Trowbridge J, Rudisill J, Dorschner RA, et al. (2001). Innate antimicrobial peptide protects the skin from invasive bacterial infection. *Nature* 414:454-457.

Oppenheim FG, Xu T, McMillian FM, Levitz SM, Diamond RD,

Offner GD, *et al.* (1988). Histatins, a novel family of histidine-rich proteins in human parotid secretion. Isolation, characterization, primary structure, and fungistatic effects on *Candida albicans. J Biol Chem* 263:7472-7477.

- Pestonjamasp VK, Huttner KH, Gallo RL (2001). Processing site and gene structure for the murine antimicrobial peptide *CRAMP*. *Peptides* 22:1643-1650.
- Putsep K, Carlsson G, Boman HG, Anderson M (2002). Deficiency of antibacterial peptides in patients with *morbus Kostmann*: an observation study. *Lancet* 360:1144-1149.
- Sahasrabudhe KS, Kimball JR, Morton TH, Weinberg A, Dale BA (2000). Expression of the antimicrobial peptide, human betadefensin 1, in duct cells of minor salivary glands and detection in saliva. J Dent Res 79:1669-1674.
- Tanaka D, Miyasaki KT, Lehrer RI (2000). Sensitivity of Actinobacillus actinomycetemcomitans and Capnocytophaga spp. to the bactericidal action of LL-37: a cathelicidin found in human leukocytes and epithelium. Oral Microbiol Immunol 15:226-231.
- Tobgi RS, Samaranayake LP, MacFarlane TW (1988). In vitro susceptibility of Candida species to lysozyme. *Oral Microbiol Immunol* 3:35-39.
- Turner J, Cho Y, Dinh NN, Waring AJ, Lehrer RI (1998). Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. *Antimicrob Agents Chemother* 42:2206-2214.
- vanderSpek JC, Offner GD, Troxler RF, Oppenheim FG (1990). Molecular cloning of human submandibular histatins. Arch Oral Biol 35:137-143.
- Weinberg A, Krisanaprakornkit S, Dale BA (1998). Epithelial antimicrobial peptides: review and significance for oral applications. *Crit Rev Oral Biol Med* 9:399-414.
- Yang D, Chertov O, Oppenheim JJ (2001). Participation of mammalian defensins and cathelicidins in anti-microbial immunity: receptors and activities of human defensins and cathelicidin (LL-37). J Leukoc Biol 69:691-697.
- Zanetti M, Gennaro R, Romeo D (1995). Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. *FEBS Lett* 374:1-5.
- Zasloff M (2002). Antimicrobial peptides of multicellular organism. *Nature* 415:389-395.
- Zhao C, Wang I, Lehrer RI (1996). Widespread expression of betadefensin hBD-1 in human secretory glands and epithelial cells. *FEBS Lett* 396:319-322.